Business briefs: Xeljanz, Merck, Pfizer

Share this article:

Five more countries have approved Pfizer's RA pill Xeljanz.  Russia, Argentina, Kuwait, the United Arab Emirates and Switzerland will all allow the twice-a-day pill for patients who are not responding to already available treatments. Xeljanz is about to be launched in Japan, and was launched in the U.S. this past November.

Merck presented positive data on its investigational BACE Inhibitor MK-8931 for Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) in Boston this week. MK-8931 demonstrated reduced levels of cerebrospinal fluid in patients during their Phase I trial.  BACE Inhibitor therapies have become increasingly popular in Alzheimer's as amyloid-targeting therapies from Eli Lilly, Pfizer and Johnson & Johnson have all failed to show efficacy in clinical trials. The AAIC runs until July 18.

NICE said no thanks to Pfizer's bone cancer drug Bosulif today, citing a lofty price tag.  NICE, Britain's state health service and the country's cost agency said in new preliminary draft guidance that the cancer therapy didn't offer enough value for patients with chronic myeloid leukemia (CML) compared to other therapies. NICE's chief executive, Sir Andrew Dillon, said in a statement: “CML is a chronic condition, meaning the drugs will be used for a long period of time and even with the proposed patient access scheme, which reduces the overall cost of treatment, bosutinib doesn't offer enough benefit to justify its price…limitations in the evidence provided by the manufacturer meant that the actual benefit compared to other treatment in terms of the estimated effect on overall survival was unclear.” NICE has currently approved both Gleevec and Tasigna for CML.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.